
根据联邦政府最新发布的数据,近一半服用减肥药的美国人改变了用药方式,主要原因是费用高昂或难以获得药物。
Nearly half of Americans taking weight-loss drugs modify how they use the medications, primarily because of cost or difficulty obtaining them, according to new federal data.
美国疾病控制与预防中心(CDC)周四发布的一份报告显示,约44%服用Zepbound(泽布替尼)和Wegovy(司美格鲁肽)等GLP-1类药物的人表示,他们偏离了处方用药方案,包括漏服剂量或延迟续方。
About 44% of people taking GLP-1 medications like Zepbound and Wegovy reported deviating from their prescribed regimens, including skipping doses or delaying prescription refills, according to a Centers for Disease Control and Prevention report published on Thursday.
报告还发现,五分之一以上的使用者表示曾服用复方版本的药物,这些药物未经美国监管机构对安全性、有效性或质量进行审查。另有9%的使用者不确定自己服用的药物是否为复方药。
The report also found that more than one in five users said they had taken compounded versions of the drugs, which have not been reviewed by US regulators for safety, effectiveness or quality. Another 9% weren’t sure whether their medications were compounded.
这些发现凸显了患者面临的挑战。这类药物改变了肥胖症和糖尿病的治疗格局,但高昂的价格、有限的保险覆盖范围以及此前的药物短缺,使得获取药物变得复杂。
The findings underscore the challenges facing patients. The drugs have transformed treatment for obesity and diabetes, but high prices, limited insurance coverage and previous shortages have complicated access.
根据对8118名成年人在2025年7月和8月进行的一项调查,约十分之一的美国成年人表示在过去一年服用过GLP-1类药物。该调查是在礼来公司和诺和诺德公司加大力度增加供应、抵御销售更便宜复方替代品的公司竞争之前进行的。联邦政府也一直在努力改善获取渠道,包括为参加联邦医疗保险(Medicare,面向美国老年人的政府医保计划)的患者改善获取渠道。
About one in 10 US adults reported taking a GLP-1 medication during the previous year, according to a survey of 8,118 adults conducted in July and August 2025. It was conducted before drugmakers like Eli Lilly & Co. and Novo Nordisk A/S ramped up efforts to increase availability and fend off competition from companies selling cheaper compounded alternatives. The federal government has also worked to improve access, including for patients with Medicare, the government health plan for older Americans.
漏服剂量是最常见的改变方式,28%的使用者报告了这种情况。礼来和诺和诺德的注射剂本应每周服用一次,漏服可能会影响治疗效果。研究人员表示,需要更多研究来了解用药时间表的改变是否影响药物的安全性和有效性。
Skipping doses was the most common modification, reported by 28% of users. The Lilly and Novo shots are meant to be taken weekly, and skipping doses can impact treatment. Researchers said more studies are needed to understand whether the changes to dosing schedules affect the safety and effectiveness of the drugs.
根据疾控中心的数据,在改变用药方式的人群中,38%的人表示是因为费用,36%的人则归因于药物供应问题。
Among those who changed how they took their medications, 38% cited cost and 36% pointed to availability, according to the CDC.
年轻成年人尤其有可能改变治疗方案。约54%的18至39岁使用者表示调整了药物使用。在做出改变的年轻成年人中,58%将费用列为障碍。
Younger adults were particularly likely to alter their treatment. About 54% of users aged 18 to 39 reported modifying their medication use. Among younger adults who made changes, 58% cited cost as a barrier.
报告还揭示了复方GLP-1药物的广泛使用,这类药物在品牌药短缺期间变得流行。服用复方药物的患者比服用品牌药的患者更有可能表示改变了用药方式。
The report also sheds light on the widespread use of compounded GLP-1s, which became popular during shortages of branded medications. Patients taking compounded medications were more likely to report altering their use than those on brand-name drugs.